Innate Pharma SA
IPHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001598599
No open-market purchases or sales by Innate Pharma SA insiders were filed in the last 90 days; 10 institutions reported holding it in 13F filings for Q2 2026, worth $354.0K in total; no superinvestor holds it.
Other share classesIPHYF
Q4 2022 vs. Q3 2022
How the institutions holding Innate Pharma SA changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 12 | 11 | −1 |
| Shares | 944.5K | 399.9K | −544.6K (−57.7%) |
| Value | $1.89M | $1.49M | −$397.9K (−21.1%) |
New holders (2)
Institutions that held Innate Pharma SA at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 13,315 | $49.7K | 0.00% |
| Tower Research Capital LLC (TRC) | 2,954 | $11.0K | 0.00% |
Sold out (3)
Institutions that held Innate Pharma SA at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| BlackRock Inc. | 482,645 | $965.0K |
| Two Sigma Investments, LP | 18,789 | $38.0K |
| Balyasny Asset Management LLC | 16,094 | $32.0K |